Chairman of the Board
My long career has been spent building a number of science, technology and investment companies. I am the founder of IP Group plc, one of the UK’s leading technology commercialisation businesses. I also founded Oxford Sciences Innovation, the largest university venture fund worldwide.
Following my graduation from Keble College, University of Oxford, where I read History I joined city investment bank Bankers’ Trust. Since then I have been a founder and/or director of many UK technology companies including Oxford Nanopore, Proximagen, Synairgen, Ilika, Oxford Catalysts and Plectrum Petroleum (acquired by Cairn Energy). Chess has always been a passion of mine and I was awarded the International Master title and International Grandmaster titles in the mid and late eighties. Currently I am a member of the Internet Chess Club and have on a number of occasions captained, managed, or sponsored the England Squad in major team events such as the Olympiad.
Prof. Peter Donnelly
Founder & CEO
I am CEO of Genomics plc and Professor of Statistical Science at the University of Oxford. My research involves the analysis of genomic data to understand human disease, human biology, and human history.
After growing up in Australia, I studied for a doctorate in Mathematics in Oxford, as a Rhodes Scholar. My work has focussed on genetics and genomics for the last 15 years, and I feel incredibly fortunate to be involved in one of the most exciting areas of science. I’m now excited to be building a company that translates some of those discoveries, and produces direct benefit to patients. From 2007 to 2018 I was Director of the Wellcome Centre for Human Genetics in Oxford. It is an honour to have been elected as a Fellow of the Royal Society, and of the Academy of Medical Sciences, and an Honorary Fellow of the Institute of Actuaries. I am proud of having played a leading role in some of the major national and international genomics projects, including the HapMap Project, and the Wellcome Trust Case Control Consortium. The main paper from the Consortium – which I chaired – won several awards, including Scientific American’s Research Leader of the Year, The Lancet’s Paper of the Year, and the Amadeo Prize. My TED talk has (scarily) been viewed a million times. Beyond work, I love being with my kids, playing and watching sport, cooking and dancing (badly).
Papers and Talks
Genetics, genomics, and human disease
Prof. Gil McVean
Founder & Chief Information Officer
I am responsible for how data is used within Genomics plc. My main expertise is in statistical genetics, human genome variation and evolution.
I help organise and run the 1,000 Genomes Project, which is mapping human genomic variation. I’m also part of the Global Alliance for Genomics and Health where I help establish methods and protocols for storing and exchanging genomic data with linked medical information.
Along with my Francis Crick lecture at the Royal Society, one of my proudest moments was a 2004 paper showing recombination hotspots in humans.
Outside work, my passions lay in family, natural history and various forms of sourdough.
Dr. Jeff Barrett
CSO & Director
I built a fifteen year career at the world's biggest academic genome centres to understand how genomics can help us figure out human disease. I see Genomics plc as uniquely placed to translate that research into improved human health, and am excited about driving our scientific strategy as CSO.
After a degree in physics from MIT I worked as a programmer and analyst during the founding years of the Broad Institute. I moved to Oxford where I received a D.Phil. in statistical genetics, and then to the Wellcome Sanger Institute, near Cambridge. I have led some of the largest genome-sequencing studies in the world, working to understand how genetic variation influences human diseases ranging from infection and inflammation to autism and schizophrenia. My academic work has been cited more than 65,000 times.
From 2015 to early 2018 I was Head of Open Targets, a unique, pre-competitive partnership of the Sanger Institute, European Bioinformatics Institute, GSK, Biogen and Takeda. Together we systematically improved the identification and prioritisation of drug targets for safe and effective medicines by combining large-scale genomic experiments with objective statistical and computational techniques. I see my move to Genomics plc as the next phase of that journey to use genomics to transform drug discovery.
Links to some of my work:
Video of a keynote at Discovery on Target:
Dr. David Altshuler
I am the Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals, and lead Vertex’s research efforts aimed at discovering new medicines for the treatment of CF and other serious diseases, overseeing the company’s three research sites in Boston, San Diego and Oxford, UK.
I was previously one of four founding members, Deputy Director and Chief Academic Officer at the Broad Institute of Harvard and MIT, a professor at Harvard and MIT, and a physician at Massachusetts General Hospital. I was also a leader of the SNP Consortium, HapMap and 1,000 Genome Projects, and discovered over 100 gene variants associated with type 2 diabetes and other common diseases. I’m a member of the National Academy of Medicine and the American Academy of Arts and Sciences, and have been named a Champion of Change by the White House for my leadership in creating and leading the Global Alliance for Genomic and Health.
Dr. Sam Williams
I have over 20 years' experience in the biotechnology industry, both as a top-ranked equity analyst in the City of London and, subsequently, as a chief executive and investor.
I am Executive Chairman of Istesso Limited, a London-based drug-discovery company, and Head of Life Sciences at IP Group where I serve as Chairman of portfolio companies Iksuda Ltd and Microbiotica Ltd, and as a non-executive director of Diurnal Group plc. I have a PhD in molecular biology from Cambridge and a degree in biology from Oxford.
I founded Foresite Capital in 2011 to merge my entrepreneurial experience and networks gained from 25 years in healthcare investing
Throughout my career, I have excelled at systematic and deep technical analysis of healthcare opportunities, while supporting the growth of companies from small enterprises into enduring franchises. My goal is for Foresite Capital and each of its portfolio companies to deliver important novel products to address critical needs in our healthcare system.
Dr. Stephen Knight
I joined F-Prime Capital in 2003 where I serve as President and Managing Partner.
I have worked in the pharmaceutical and biotechnology industries for over 25 years and invest broadly across healthcare. I serve on the Board of Directors of Beam Therapeutics, Iora Health, Pulmocide, Sana Biotechnology, and Semma Therapeutics. I have held various senior management roles in private and public biotechnology and consulting companies, and also have experience in the research sector.